Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2022 | Intramuscular COVID-19 vaccination in patients with severe hemophilia A

Susan Halimeh • 11 Jul 2022
ISTH 2022
Hemophilia Vaccines

Susan Halimeh, MD, Gerinnungszentrum Rhein-Ruhr, Duisburg, Germany, briefly discusses the results of a study that showed that COVID-19 vaccines could be administered via intramuscular injection in patients with severe hemophilia A. This interview took place at the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2022 held in London, UK.

More from Susan Halimeh

Simoctocog alfa for the treatment of patients with hemophilia A
0:44
Simoctocog alfa for the treatment of patients with hemophilia A
Susan Halimeh • 11 Jul 2022
Highlights from ISTH: gene therapy in hemophilia A & undiagnosed bleeding disorders in pediatrics
1:09
Highlights from ISTH: gene therapy in hemophilia A & undiagnosed bleeding disorders in pediatrics
Susan Halimeh • 11 Jul 2022
Managing pregnant women with vWD
0:59
Managing pregnant women with vWD
Susan Halimeh • 11 Jul 2022
Challenges in vWD: new guidelines & managing women with vWD
1:23
Challenges in vWD: new guidelines & managing women with vWD
Susan Halimeh • 12 Jul 2022

Related Videos

Importance of long-term surveillance after gene therapy in patients with hemophilia
5:45
Importance of long-term surveillance after gene therapy in patients with hemophilia
Radek Kaczmarek • 20 Jul 2026
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
4:58
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
Radek Kaczmarek • 20 Jul 2026
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
5:18
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026
Understanding potential malignancy risk following AAV gene therapy in hemophilia
7:23
Understanding potential malignancy risk following AAV gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals